PROTEINASE 3 PR1 PEPTIDE
Refractory Anemia With Excess Blasts in Transformation
National Cancer Institute (NCI)vaccinePhase 1/2Dormant
CCC
52/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 37/ 100
- Competitive Position
- 95/ 100
Competitive context
0 Active assets in the Refractory Anemia With Excess Blasts in Transformation cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Cytosin-Arabinosid National Cancer Institute (NCI) | Phase 3 | BBB |
FILGRASTIM Masonic Cancer Center, University of Minnesota | Phase 3 | BBB |
Fludarabine Nohla Therapeutics, Inc. | Phase 3 | BB |
Daunorubicin National Cancer Institute (NCI) | Phase 3 | BB |
Idarubicine National Cancer Institute (NCI) | Phase 3 | BB |
View all 32 →
Same molecule, other indications
PROTEINASE 3 PR1 PEPTIDE is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →